Following a review of strategies and care delivery models that could help optimize the management of PAH, Marius Hoeper, MD, discusses his recent publication on the long-term impact of sotatercept on morbidity and mortality.
Video content above is prompted by the following questions:
Echocardiographic Assessment Shows Promise as Risk Predictor in PAH
August 29th 2025Close to 40% of patients with right heart failure and pulmonary arterial hypertension (PAH) who remain critically ill and require admittance to the intensive care unit die within 1 year of that hospitalization.
Read More
Tricuspid Regurgitation Reliable Prognostic Indicator of PAH Severity
August 13th 2025Despite knowledge of the benefits of right heart hemodynamic measures for evaluating patient prognosis in the setting of pulmonary arterial hypertension (PAH), gaps remain in a defined role for tricuspid regurgitation as it relates to echocardiographic phenotype.
Read More
Lung Transplant Referrals Lag for High-Risk Patients With PAH
July 18th 2025Despite recommendations on early referral for lung transplantation in cases of pulmonary arterial hypertension (PAH), there is a lack of in-depth understanding of this current landscape; in this analysis, clinical parameter data were used to compare outcomes between patients who were and were not referred for lung transplantation.
Read More